Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad) Buy CPRX Stock  Free CPRX Stock Alerts

Catalyst Pharmaceuticals (CPRX) Financials

Catalyst Pharmaceuticals logo
$24.84 +0.57 (+2.35%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$24.78 -0.06 (-0.26%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Catalyst Pharmaceuticals

Annual Income Statements for Catalyst Pharmaceuticals

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -20 -18 -18 -34 32 75 39 83 71 164
Consolidated Net Income / (Loss)		 -20 -18 -18 -34 32 75 39 83 71 164
Net Income / (Loss) Continuing Operations		 -20 -18 -18 -34 32 75 39 83 71 164
Total Pre-Tax Income 		-20 -18 -18 -34 33 42 53 105 95 216
Total Operating Income		 -20 -19 -19 -35 32 41 52 102 87 195
Total Gross Profit		 0.00 0.00 0.00 0.50 88 102 119 180 346 423
Total Revenue		 0.00 0.00 0.00 0.50 102 119 141 214 398 492
Operating Revenue		 0.00 0.00 0.00 0.50 102 119 141 214 398 492
Total Cost of Revenue		 0.00 0.00 0.00 0.00 15 17 22 34 52 69
Operating Cost of Revenue		 - - - 0.00 15 17 22 34 52 69
Total Operating Expenses		 20 19 19 36 56 61 67 78 259 228
Selling, General & Admin Expense		 8.60 7.91 7.30 16 37 44 50 57 134 178
Research & Development Expense		 12 11 11 20 19 16 17 20 93 13
Amortization Expense		 - - - - - - 0.00 1.10 33 37
Total Other Income / (Expense), net		 0.17 1.21 0.27 1.29 1.59 0.59 0.28 2.88 7.70 21
Other Income / (Expense), net		 0.17 1.21 0.27 1.29 1.59 0.59 0.28 2.88 7.70 21
Income Tax Expense		 0.00 0.00 0.00 0.00 1.53 -33 13 22 23 52
Basic Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.31 $0.72 $0.38 $0.80 $0.67 $1.38
Weighted Average Basic Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 102.94M 103.51M 103.38M 103.37M 106.28M 118.46M
Diluted Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.30 $0.71 $0.37 $0.75 $0.63 $1.31
Weighted Average Diluted Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 106.02M 106.24M 107.80M 111.38M 113.75M 124.94M
Weighted Average Basic & Diluted Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 103.41M 103.82M 102.74M 105.65M 117.86M 121.45M

Quarterly Income Statements for Catalyst Pharmaceuticals

This table shows Catalyst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 23 25 30 38 -31 35 23 41 44 56
Consolidated Net Income / (Loss)		 23 25 30 38 -31 35 23 41 44 56
Net Income / (Loss) Continuing Operations		 23 25 30 38 -31 35 23 41 44 56
Total Pre-Tax Income 		26 33 37 49 -38 47 29 56 57 74
Total Operating Income		 25 31 36 47 -37 42 27 54 51 63
Total Gross Profit		 48 50 75 88 89 95 86 107 109 120
Total Revenue		 57 61 85 100 103 111 99 123 129 142
Operating Revenue		 57 61 85 100 103 111 99 123 129 142
Total Cost of Revenue		 9.67 11 9.95 12 14 16 13 15 19 22
Operating Cost of Revenue		 9.67 11 9.95 12 14 16 13 15 19 22
Total Operating Expenses		 22 19 40 41 126 53 59 53 59 57
Selling, General & Admin Expense		 14 14 30 28 34 42 47 41 46 44
Research & Development Expense		 8.31 4.09 3.56 3.95 84 1.97 2.58 2.99 3.28 3.80
Amortization Expense		 0.52 0.58 6.53 8.49 8.49 9.06 9.34 9.34 9.35 9.34
Total Other Income / (Expense), net		 0.91 2.21 1.70 1.81 -0.83 5.02 1.96 1.54 6.30 11
Other Income / (Expense), net		 0.91 2.21 1.70 1.81 -0.83 5.02 1.96 1.54 6.30 11
Income Tax Expense		 3.26 7.54 7.75 11 -7.26 12 5.81 15 13 18
Basic Earnings per Share		 $0.22 $0.24 $0.28 $0.36 ($0.29) $0.32 $0.20 $0.35 $0.37 $0.46
Weighted Average Basic Shares Outstanding		 103.32M 103.37M 105.56M 106.26M 106.57M 106.28M 116.81M 118.18M 118.93M 118.46M
Diluted Earnings per Share		 $0.20 $0.23 $0.26 $0.33 ($0.29) $0.33 $0.19 $0.33 $0.35 $0.44
Weighted Average Diluted Shares Outstanding		 111.99M 111.38M 113.99M 113.67M 106.57M 113.75M 123.40M 124.66M 125.41M 124.94M
Weighted Average Basic & Diluted Shares Outstanding		 104.07M 105.65M 106.08M 106.58M 106.61M 117.86M 118.12M 118.69M 119.27M 121.45M

Annual Cash Flow Statements for Catalyst Pharmaceuticals

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 19 -14 44 -41 73 41 41 127 -161 380
Net Cash From Operating Activities		 -18 -18 -14 -26 35 45 60 116 144 240
Net Cash From Continuing Operating Activities		 -18 -18 -14 -26 35 45 60 116 144 240
Net Income / (Loss) Continuing Operations		 -20 -18 -18 -34 32 75 39 83 71 164
Consolidated Net Income / (Loss)		 -20 -18 -18 -34 32 75 39 83 71 164
Depreciation Expense		 0.03 0.04 0.05 0.04 0.06 0.09 0.19 0.14 0.32 0.40
Amortization Expense		 - - - 0.00 0.24 0.00 0.00 1.10 33 37
Non-Cash Adjustments To Reconcile Net Income		 1.52 0.95 2.59 3.11 3.26 6.12 7.22 13 94 16
Changes in Operating Assets and Liabilities, net		 0.66 -0.88 2.03 4.71 -0.82 -36 13 19 -55 22
Net Cash From Investing Activities		 -0.01 3.55 -0.00 -15 37 -5.01 -11 9.21 -294 -0.56
Net Cash From Continuing Investing Activities		 -0.01 3.55 -0.00 -15 37 -5.01 -11 9.21 -294 -0.56
Purchase of Property, Plant & Equipment		 -0.02 -0.10 - -0.09 -0.02 -0.01 -1.02 -0.03 -0.23 -0.56
Acquisitions		 - - - - - - 0.00 -10 -280 0.00
Sale and/or Maturity of Investments		 0.02 - - 22 72 5.00 0.00 19 0.00 0.00
Other Investing Activities, net		 -0.00 3.72 - - - 0.00 0.00 0.00 -13 0.00
Net Cash From Financing Activities		 37 0.07 57 0.29 1.12 0.70 -8.14 1.69 -11 141
Net Cash From Continuing Financing Activities		 37 0.07 57 0.29 1.12 0.70 -8.14 1.69 -11 141
Repurchase of Common Equity		 - - - - 0.00 0.00 -12 -6.91 0.00 -0.30
Issuance of Common Equity		 35 - 54 - - - - 0.00 0.00 141
Other Financing Activities, net		 2.29 0.07 3.58 0.29 1.12 0.70 3.95 8.60 -11 -0.04
Cash Interest Paid		 - - - - - - 0.00 0.00 0.71 1.40
Cash Income Taxes Paid		 - - - 0.00 0.00 2.79 3.00 7.67 50 68

Quarterly Cash Flow Statements for Catalyst Pharmaceuticals

This table details how cash moves in and out of Catalyst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 45 42 -150 31 -58 17 173 65 67 75
Net Cash From Operating Activities		 41 40 12 31 45 56 32 64 73 71
Net Cash From Continuing Operating Activities		 41 40 12 31 45 56 32 64 73 71
Net Income / (Loss) Continuing Operations		 23 25 30 38 -31 35 23 41 44 56
Consolidated Net Income / (Loss)		 23 25 30 38 -31 35 23 41 44 56
Depreciation Expense		 0.04 0.04 0.07 0.08 0.08 0.08 0.09 0.09 0.11 0.11
Amortization Expense		 0.52 0.58 6.53 8.49 8.49 9.06 9.34 9.34 9.35 9.34
Non-Cash Adjustments To Reconcile Net Income		 6.31 1.91 3.00 3.45 85 3.04 9.52 6.78 1.56 -1.61
Changes in Operating Assets and Liabilities, net		 12 12 -27 -19 -17 8.62 -10 7.13 18 7.10
Net Cash From Investing Activities		 -0.13 - -162 - -93 -38 -0.20 -0.01 -0.26 -0.09
Net Cash From Continuing Investing Activities		 -0.13 - -162 - -93 -38 -0.20 -0.01 -0.26 -0.09
Purchase of Property, Plant & Equipment		 - - -0.07 - -0.06 -0.09 -0.20 -0.01 -0.26 -0.09
Net Cash From Financing Activities		 3.98 2.25 0.15 -0.21 -10 -0.67 141 1.16 -5.97 4.43
Net Cash From Continuing Financing Activities		 3.98 2.25 0.15 -0.21 -10 -0.67 141 1.16 -5.97 4.43
Other Financing Activities, net		 3.98 2.25 0.15 -0.21 -10 -0.67 0.35 1.16 -5.97 4.43
Cash Interest Paid		 - - 0.00 - 0.65 0.06 0.07 0.08 1.16 0.09
Cash Income Taxes Paid		 0.50 1.32 - - 14 8.80 - - 18 17

Annual Balance Sheets for Catalyst Pharmaceuticals

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 60 42 85 60 112 192 238 376 470 851
Total Current Assets		 60 41 85 55 111 159 210 321 219 624
Cash & Equivalents		 28 14 57 17 90 130 171 298 138 518
Accounts Receivable		 - - - - 11 5.99 6.62 10 54 65
Inventories, net		 - - 0.00 0.06 1.96 4.65 7.87 6.81 16 20
Prepaid Expenses		 1.50 1.05 1.17 1.65 4.35 8.33 4.35 5.17 13 21
Plant, Property, & Equipment, net		 0.19 0.24 0.19 0.25 0.21 0.13 0.96 0.85 1.20 1.35
Total Noncurrent Assets		 0.01 0.01 0.01 5.02 0.80 33 27 54 250 226
Long-Term Investments		 - - 0.00 5.01 - - - 0.00 16 22
Intangible Assets		 - - - - - - 0.00 32 194 157
Noncurrent Deferred & Refundable Income Taxes		 - - - - 0.00 33 24 19 37 46
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.01 0.80 0.01 3.03 2.77 2.51 2.23
Total Liabilities & Shareholders' Equity		 60 42 85 60 112 192 238 376 470 851
Total Liabilities		 4.63 2.40 4.42 9.67 25 23 31 75 82 124
Total Current Liabilities		 3.44 2.09 4.27 9.51 24 23 27 58 76 121
Accounts Payable		 1.79 0.93 1.95 2.34 4.12 4.26 2.77 3.98 15 17
Accrued Expenses		 1.65 1.16 2.32 7.17 20 19 24 54 61 104
Total Noncurrent Liabilities		 1.18 0.30 0.16 0.15 0.65 0.00 3.89 18 6.17 3.10
Other Noncurrent Operating Liabilities		 1.18 0.30 0.16 0.15 0.65 0.00 3.89 18 6.17 3.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 55 39 81 51 88 170 207 300 388 728
Total Preferred & Common Equity		 55 39 81 51 88 170 207 300 388 728
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 55 39 81 51 88 170 207 300 388 728
Common Stock		 146 147 208 211 216 223 233 251 267 442
Retained Earnings		 -90 -108 -127 -161 -129 -54 -26 50 121 285
Accumulated Other Comprehensive Income / (Loss)		 - - - -0.02 0.01 0.03 -0.15 0.02 0.01 0.06

Quarterly Balance Sheets for Catalyst Pharmaceuticals

This table presents Catalyst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 333 407 444 413 647 706 772
Total Current Assets		 276 199 241 192 405 474 539
Cash & Equivalents		 256 148 179 121 310 376 442
Accounts Receivable		 9.34 33 43 48 60 57 58
Inventories, net		 7.13 10 11 9.04 20 18 20
Prepaid Expenses		 3.78 6.93 8.63 14 14 24 18
Plant, Property, & Equipment, net		 0.88 1.29 1.20 1.19 1.31 1.23 1.38
Total Noncurrent Assets		 56 207 202 220 241 231 232
Long-Term Investments		 - - - 13 15 13 15
Intangible Assets		 33 184 176 167 185 175 166
Noncurrent Deferred & Refundable Income Taxes		 20 20 23 37 38 40 48
Other Noncurrent Operating Assets		 2.84 2.71 2.64 2.58 2.44 2.37 2.30
Total Liabilities & Shareholders' Equity		 333 407 444 413 647 706 772
Total Liabilities		 63 74 69 65 85 98 111
Total Current Liabilities		 45 57 53 58 80 92 105
Accounts Payable		 2.53 3.39 4.42 4.60 10 7.12 12
Accrued Expenses		 42 53 48 53 69 85 94
Total Noncurrent Liabilities		 18 17 16 6.86 5.70 5.39 5.67
Other Noncurrent Operating Liabilities		 18 17 16 6.86 5.70 5.39 5.67
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 270 334 375 349 561 609 661
Total Preferred & Common Equity		 270 334 375 349 561 609 661
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 270 334 375 349 561 609 661
Common Stock		 246 254 258 262 417 423 432
Retained Earnings		 24 79 117 86 145 185 229
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.01 0.02 0.02 0.00 0.00 0.00

Annual Metrics and Ratios for Catalyst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 20,361.20% 16.39% 18.27% 52.10% 85.90% 23.49%
EBITDA Growth		 -30.46% 10.74% -1.87% -84.93% 199.24% 24.55% 25.91% 100.45% 20.23% 99.41%
EBIT Growth		 -30.46% 10.68% -1.88% -84.68% 198.25% 25.39% 25.73% 98.83% -9.75% 128.82%
NOPAT Growth		 -39.80% 5.48% 3.11% -88.95% 222.89% 143.50% -46.88% 105.74% -18.81% 125.44%
Net Income Growth		 -30.46% 10.68% -1.88% -84.68% 193.74% 135.24% -47.35% 110.42% -14.05% 129.50%
EPS Growth		 -4.17% 12.00% 4.55% -57.14% 190.91% 136.67% -47.89% 102.70% -16.00% 107.94%
Operating Cash Flow Growth		 -39.20% 0.29% 23.50% -90.27% 232.37% 30.11% 34.06% 92.22% 23.74% 67.00%
Free Cash Flow Firm Growth		 -81.07% 0.47% 27.39% -80.26% 247.35% 27.68% 40.56% 77.90% -276.12% 216.24%
Invested Capital Growth		 27.59% 62.44% -178.02% -152.69% 10.61% 525.62% -46.91% -86.98% 11,437.81% -19.35%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 40.75% 0.75% 5.46% 11.71% 14.30% 6.79%
EBITDA Q/Q Growth		 -13.02% 8.42% -7.17% -36.63% 219.71% -1.26% 10.18% 24.39% 21.14% 12.28%
EBIT Q/Q Growth		 -12.98% 8.37% -7.12% -36.61% 218.06% 0.77% 8.42% 23.89% 16.95% 14.55%
NOPAT Q/Q Growth		 -12.14% 8.87% -6.85% -35.94% 238.36% 81.69% -5.00% 21.81% 12.54% 12.37%
Net Income Q/Q Growth		 -12.98% 8.37% -7.12% -36.61% 237.44% 4.91% -5.11% 24.15% 15.11% 14.77%
EPS Q/Q Growth		 -8.70% 12.00% -5.00% -32.00% 233.33% 4.41% -5.13% 22.95% 18.87% 9.17%
Operating Cash Flow Q/Q Growth		 -3.75% 1.21% 2.70% -19.80% 147.79% 1.84% 11.18% 21.97% 12.16% 6.78%
Free Cash Flow Firm Q/Q Growth		 -0.96% -0.25% 6.54% -12.99% 197.29% 396.22% 12.85% 23.76% -16.65% 35.51%
Invested Capital Q/Q Growth		 -26.27% 40.42% -40.06% -195.66% -92.90% -0.67% -34.79% -85.50% 8.89% -7.49%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 85.57% 85.69% 84.46% 83.94% 86.95% 86.00%
EBITDA Margin		 0.00% 0.00% 0.00% -6,793.11% 32.95% 35.26% 37.53% 49.47% 31.99% 51.66%
Operating Margin		 0.00% 0.00% 0.00% -7,059.03% 31.11% 34.69% 37.20% 47.54% 21.80% 39.68%
EBIT Margin		 0.00% 0.00% 0.00% -6,800.70% 32.66% 35.18% 37.40% 48.89% 23.73% 43.98%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -6,800.70% 31.16% 62.97% 28.03% 38.79% 17.93% 33.33%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 95.41% 179.00% 74.97% 79.34% 75.56% 75.78%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 4.59% -79.00% 25.03% 20.66% 24.44% 24.22%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 659.19% 174.98% 918.58% 55.64% 70.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 658.30% 174.86% 917.64% 53.07% 65.41%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -600.89% -154.01% -885.82% -34.89% -40.65%
Return on Equity (ROE)		 -44.61% -38.13% -30.62% -51.62% 46.06% 58.30% 20.98% 32.76% 20.75% 29.38%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 128.66% 236.27% 1,072.51% -140.92% 91.46%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -46.63% 38.66% 27.49% 24.49% 34.14% 22.35% 32.73%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -46.63% 36.89% 49.21% 18.36% 27.09% 16.89% 24.80%
Return on Common Equity (ROCE)		 -44.61% -38.13% -30.62% -51.62% 46.06% 58.30% 20.98% 32.76% 20.75% 29.38%
Return on Equity Simple (ROE_SIMPLE)		 -36.47% -45.98% -22.74% -66.96% 36.37% 44.21% 19.09% 27.65% 18.41% 22.52%
Net Operating Profit after Tax (NOPAT)		 -14 -13 -13 -25 30 74 39 81 66 148
NOPAT Margin		 0.00% 0.00% 0.00% -4,941.32% 29.68% 62.09% 27.88% 37.72% 16.47% 30.07%
Net Nonoperating Expense Percent (NNEP)		 -12.19% -9.26% -8.58% -13.05% 1.98% 0.90% 0.13% 0.93% 2.57% 4.62%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 26.89% 16.91% 20.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 14.43% 14.31% 15.54% 16.06% 13.05% 14.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 3,175.19% 36.05% 37.15% 35.24% 26.65% 33.58% 36.15%
R&D to Revenue		 0.00% 0.00% 0.00% 3,983.84% 18.42% 13.85% 12.03% 9.24% 23.39% 2.57%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 7,159.03% 54.47% 51.00% 47.26% 36.40% 65.15% 46.32%
Earnings before Interest and Taxes (EBIT)		 -20 -18 -18 -34 33 42 53 105 95 216
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -18 -18 -34 34 42 53 106 127 254
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.66 2.21 4.12 3.88 4.41 2.04 3.38 6.44 4.62 3.42
Price to Tangible Book Value (P/TBV)		 3.66 2.21 4.12 3.88 4.41 2.04 3.38 7.22 9.25 4.36
Price to Revenue (P/Rev)		 0.00 0.00 0.00 394.52 3.78 2.91 4.96 9.04 4.50 5.06
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 12.12 4.62 17.68 23.30 25.10 15.19
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 8.25% 21.66% 5.66% 4.29% 3.98% 6.58%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 7.02 32.56 808.16 7.01 10.34
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 277.54 2.85 1.73 3.60 7.64 4.11 3.97
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 8.66 4.90 9.59 15.45 12.86 7.68
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 8.74 4.92 9.62 15.64 17.33 9.02
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 9.61 2.79 12.91 20.27 24.97 13.19
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 8.43 4.57 8.40 14.11 11.41 8.13
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 9.88 5.46 9.56 17.36 0.00 10.10
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.04 -1.03 -1.08 -1.11 -0.91 -0.88 -0.97 -0.66 -0.62
Leverage Ratio		 1.15 1.07 1.06 1.11 1.25 1.18 1.14 1.21 1.23 1.18
Compound Leverage Factor		 1.15 1.07 1.06 1.11 1.25 1.18 1.14 1.21 1.23 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 24.24 17.84 43.55 7.58 10.59 10.93 15.62 17.96 15.31 14.66
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.41 19.79 19.97 5.80 4.62 7.00 7.76 5.57 2.88 5.17
Quick Ratio		 16.97 19.29 19.69 5.62 4.36 6.43 7.31 5.36 2.51 4.83
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -15 -11 -20 30 38 53 94 -166 193
Operating Cash Flow to CapEx		 -76,774.86% -18,700.10% 0.00% -28,415.69% 182,168.42% 409,400.00% 5,913.03% 400,162.07% 62,164.50% 43,130.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 1.18 0.78 0.65 0.70 0.94 0.74
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 14.41 22.34 25.11 12.45 8.27
Inventory Turnover		 0.00 0.00 0.00 0.00 14.67 5.16 3.50 4.69 4.63 3.91
Fixed Asset Turnover		 0.00 0.00 0.00 2.29 448.82 699.47 258.65 237.21 390.01 385.83
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 4.57 4.07 6.23 10.20 5.54 4.39
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 25.33 16.34 14.53 29.31 44.16
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 24.89 70.77 104.42 77.87 78.84 93.27
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 79.82 89.69 58.58 35.78 65.92 83.21
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -54.93 6.41 62.18 56.62 42.23 54.23
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -2.92 -1.10 -3.05 -7.71 -6.89 29 16 2.03 234 189
Invested Capital Turnover		 0.00 0.00 0.00 -0.09 -14.02 10.62 6.28 24.35 3.38 2.33
Increase / (Decrease) in Invested Capital		 1.11 1.82 -1.95 -4.66 0.82 36 -14 -14 232 -45
Enterprise Value (EV)		 145 47 249 139 292 206 507 1,637 1,638 1,950
Market Capitalization		 203 87 333 197 386 346 698 1,936 1,792 2,489
Book Value per Share		 $0.67 $0.47 $0.95 $0.49 $0.85 $1.64 $2.01 $2.89 $3.64 $6.10
Tangible Book Value per Share		 $0.67 $0.47 $0.95 $0.49 $0.85 $1.64 $2.01 $2.57 $1.82 $4.79
Total Capital		 55 39 81 51 88 170 207 300 388 728
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -58 -40 -84 -58 -95 -140 -191 -298 -154 -539
Capital Expenditures (CapEx)		 0.02 0.10 0.00 0.09 0.02 0.01 1.02 0.03 0.23 0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.94 -1.05 -3.09 -7.81 -7.25 -3.79 -8.22 -35 5.63 -15
Debt-free Net Working Capital (DFNWC)		 56 39 81 46 87 136 183 263 143 503
Net Working Capital (NWC)		 56 39 81 46 87 136 183 263 143 503
Net Nonoperating Expense (NNE)		 5.95 4.58 5.34 9.30 -1.51 -1.05 -0.21 -2.29 -5.82 -16
Net Nonoperating Obligations (NNO)		 -58 -40 -84 -58 -95 -140 -191 -298 -154 -539
Total Depreciation and Amortization (D&A)		 0.03 0.04 0.05 0.04 0.30 0.09 0.19 1.24 33 38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -1,561.11% -7.09% -3.18% -5.84% -16.42% 1.41% -2.97%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 9,135.21% 85.30% 114.63% 129.97% 122.88% 35.98% 102.28%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 9,135.21% 85.30% 114.63% 129.97% 122.88% 35.98% 102.28%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.31 $0.72 $0.38 $0.80 $0.67 $1.38
Adjusted Weighted Average Basic Shares Outstanding		 82.88M 82.97M 102.56M 102.74M 102.94M 103.51M 103.38M 103.37M 106.28M 118.46M
Adjusted Diluted Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.30 $0.71 $0.37 $0.75 $0.63 $1.31
Adjusted Weighted Average Diluted Shares Outstanding		 82.88M 82.97M 102.56M 102.74M 106.02M 106.24M 107.80M 111.38M 113.75M 124.94M
Adjusted Basic & Diluted Earnings per Share		 ($0.25) ($0.22) ($0.21) ($0.33) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 80.86M 82.88M 85.80M 102.63M 103.41M 103.82M 102.74M 105.65M 117.86M 121.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -13 -13 -25 30 29 39 81 66 148
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -4,941.32% 29.68% 24.28% 27.88% 37.72% 16.47% 30.07%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -6,800.70% 32.66% 35.18% 37.40% 48.89% 23.73% 43.98%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.62% 8.31% 0.00% 0.18%

Quarterly Metrics and Ratios for Catalyst Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Catalyst Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 59.21% 58.60% 98.12% 87.49% 79.39% 81.98% 15.40% 23.23% 25.33% 28.27%
EBITDA Growth		 88.33% 161.74% 151.03% 101.83% -210.89% 66.11% -12.28% 14.26% 326.31% 49.76%
EBIT Growth		 84.81% 157.61% 113.72% 71.75% -246.20% 41.50% -22.04% 15.00% 250.46% 58.82%
NOPAT Growth		 113.60% 156.74% 114.25% 66.24% -218.56% 30.86% -23.08% 9.12% 250.03% 52.36%
Net Income Growth		 120.23% 173.62% 123.31% 74.67% -235.24% 36.80% -21.28% 8.03% 242.65% 60.53%
EPS Growth		 100.00% 155.56% 116.67% 65.00% -245.00% 43.48% -26.92% 0.00% 220.69% 33.33%
Operating Cash Flow Growth		 90.27% 109.00% 42.37% 17.42% 9.27% 38.85% 164.50% 108.54% 61.48% 27.37%
Free Cash Flow Firm Growth		 99.94% 62.12% -616.42% -496.95% -811.90% -637.77% 78.83% 111.65% 122.04% 146.17%
Invested Capital Growth		 -41.45% -86.98% 726.82% 867.82% 1,436.06% 11,437.81% 27.10% 11.89% -5.08% -19.35%
Revenue Q/Q Growth		 7.78% 6.14% 40.50% 16.65% 3.12% 7.67% -10.91% 24.57% 4.88% 10.20%
EBITDA Q/Q Growth		 -6.09% 26.59% 30.60% 29.99% -151.60% 289.62% -31.03% 69.33% 2.20% 25.48%
EBIT Q/Q Growth		 -7.92% 26.92% 13.04% 30.01% -178.37% 222.85% -37.72% 91.78% 2.54% 29.68%
NOPAT Q/Q Growth		 0.41% 8.25% 18.72% 28.82% -171.61% 219.48% -30.22% 82.76% -1.54% 21.34%
Net Income Q/Q Growth		 5.22% 11.97% 16.09% 27.71% -181.47% 213.26% -33.20% 75.27% 7.57% 27.46%
EPS Q/Q Growth		 0.00% 15.00% 13.04% 26.92% -187.88% 213.79% -42.42% 73.68% 6.06% 25.71%
Operating Cash Flow Q/Q Growth		 57.69% -2.96% -69.88% 154.80% 46.74% 23.31% -42.63% 100.89% 13.62% -2.74%
Free Cash Flow Firm Q/Q Growth		 -9.60% 17.14% -461.25% -3.77% -62.13% 11.51% 85.78% 157.10% 206.65% 85.38%
Invested Capital Q/Q Growth		 -31.17% -85.50% 9,051.73% 5.98% 9.25% 8.89% 0.81% -6.69% -7.33% -7.49%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 83.12% 81.57% 88.35% 87.90% 86.20% 85.70% 87.29% 87.45% 85.02% 84.74%
EBITDA Margin		 46.40% 55.34% 51.44% 57.32% -28.68% 50.51% 39.10% 53.15% 51.79% 58.98%
Operating Margin		 43.85% 50.70% 41.71% 46.90% -36.21% 37.71% 27.54% 44.21% 39.56% 44.31%
EBIT Margin		 45.43% 54.33% 43.71% 48.72% -37.03% 42.24% 29.53% 45.46% 44.45% 52.31%
Profit (Net Income) Margin		 39.74% 41.92% 34.64% 37.92% -29.96% 31.51% 23.63% 33.24% 34.10% 39.44%
Tax Burden Percent		 87.47% 77.17% 79.24% 77.84% 80.91% 74.60% 80.01% 73.12% 76.71% 75.40%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 12.53% 22.83% 20.76% 22.16% 0.00% 25.40% 19.99% 26.88% 23.29% 24.60%
Return on Invested Capital (ROIC)		 388.69% 952.71% 81.58% 102.01% -77.25% 95.02% 43.05% 67.46% 66.79% 77.82%
ROIC Less NNEP Spread (ROIC-NNEP)		 388.32% 952.01% 80.80% 101.31% -74.82% 93.36% 42.39% 67.06% 65.15% 75.35%
Return on Net Nonoperating Assets (RNNOA)		 -356.96% -919.00% -50.48% -65.67% 47.17% -61.38% -22.45% -38.68% -38.15% -46.83%
Return on Equity (ROE)		 31.72% 33.71% 31.10% 36.34% -30.08% 33.64% 20.60% 28.78% 28.64% 30.99%
Cash Return on Invested Capital (CROIC)		 402.80% 1,072.51% -64.63% -60.83% -124.57% -140.92% 4.21% 18.82% 68.11% 91.46%
Operating Return on Assets (OROA)		 31.32% 37.94% 34.27% 41.50% -34.57% 39.78% 23.05% 34.34% 34.54% 38.93%
Return on Assets (ROA)		 27.39% 29.28% 27.16% 32.31% -27.97% 29.68% 18.44% 25.11% 26.50% 29.35%
Return on Common Equity (ROCE)		 31.72% 33.71% 31.10% 36.34% -30.08% 33.64% 20.60% 28.78% 28.64% 30.99%
Return on Equity Simple (ROE_SIMPLE)		 24.78% 0.00% 29.79% 30.79% 17.80% 0.00% 11.60% 11.20% 21.61% 0.00%
Net Operating Profit after Tax (NOPAT)		 22 24 28 36 -26 31 22 40 39 47
NOPAT Margin		 38.36% 39.12% 33.06% 36.50% -25.35% 28.13% 22.03% 32.33% 30.35% 33.41%
Net Nonoperating Expense Percent (NNEP)		 0.37% 0.70% 0.78% 0.71% -2.43% 1.65% 0.66% 0.40% 1.63% 2.47%
Return On Investment Capital (ROIC_SIMPLE)		 - 7.91% - - - 8.02% - - - 6.51%
Cost of Revenue to Revenue		 16.88% 18.43% 11.65% 12.10% 13.80% 14.30% 12.71% 12.55% 14.98% 15.26%
SG&A Expenses to Revenue		 23.84% 23.19% 34.81% 28.52% 32.68% 38.02% 47.65% 33.19% 35.65% 31.16%
R&D to Revenue		 14.52% 6.74% 4.17% 3.97% 81.47% 1.78% 2.62% 2.43% 2.55% 2.68%
Operating Expenses to Revenue		 39.27% 30.88% 46.64% 41.01% 122.42% 47.99% 59.75% 43.24% 45.46% 40.43%
Earnings before Interest and Taxes (EBIT)		 26 33 37 49 -38 47 29 56 57 74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 27 34 44 57 -29 56 39 65 67 84
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.89 6.44 5.25 3.80 3.57 4.62 3.03 3.01 3.57 3.42
Price to Tangible Book Value (P/TBV)		 5.57 7.22 11.71 7.14 6.87 9.25 4.51 4.22 4.77 4.36
Price to Revenue (P/Rev)		 6.88 9.04 6.83 4.71 3.58 4.50 4.13 4.21 5.12 5.06
Price to Earnings (P/E)		 19.71 23.30 17.62 12.34 20.08 25.10 26.10 26.85 16.52 15.19
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 5.07% 4.29% 5.67% 8.10% 4.98% 3.98% 3.83% 3.72% 6.05% 6.58%
Enterprise Value to Invested Capital (EV/IC)		 76.07 808.16 8.65 6.35 5.18 7.01 5.83 6.55 9.34 10.34
Enterprise Value to Revenue (EV/Rev)		 5.54 7.64 6.25 4.12 3.19 4.11 3.34 3.32 4.13 3.97
Enterprise Value to EBITDA (EV/EBITDA)		 12.48 15.45 12.11 7.74 10.57 12.86 11.26 11.07 8.41 7.68
Enterprise Value to EBIT (EV/EBIT)		 12.58 15.64 12.87 8.61 13.76 17.33 15.92 15.40 10.08 9.02
Enterprise Value to NOPAT (EV/NOPAT)		 16.03 20.27 16.73 11.31 19.08 24.97 23.24 23.03 14.46 13.19
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.17 14.11 13.40 10.04 8.69 11.41 8.40 7.32 8.47 8.13
Enterprise Value to Free Cash Flow (EV/FCFF)		 13.95 17.36 0.00 0.00 0.00 0.00 154.87 36.78 13.35 10.10
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.97 -0.62 -0.65 -0.63 -0.66 -0.53 -0.58 -0.59 -0.62
Leverage Ratio		 1.19 1.21 1.18 1.15 1.21 1.23 1.18 1.17 1.17 1.18
Compound Leverage Factor		 1.19 1.21 1.18 1.15 1.21 1.23 1.18 1.17 1.17 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 14.32 17.33 15.91 14.39 12.78 14.98 13.66 13.13 14.68 14.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.18 5.57 3.51 4.59 3.32 2.88 5.09 5.14 5.11 5.17
Quick Ratio		 5.94 5.36 3.20 4.22 2.92 2.51 4.66 4.69 4.75 4.83
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 32 37 -135 -140 -227 -201 -29 16 50 93
Operating Cash Flow to CapEx		 0.00% 0.00% 16,310.81% 0.00% 70,512.50% 59,836.56% 16,042.71% 641,350.00% 28,135.52% 80,542.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.69 0.70 0.78 0.85 0.93 0.94 0.78 0.76 0.78 0.74
Accounts Receivable Turnover		 24.03 25.11 11.67 11.57 12.14 12.45 8.76 8.69 8.66 8.27
Inventory Turnover		 4.34 4.69 4.24 4.61 5.86 4.63 3.60 4.03 4.34 3.91
Fixed Asset Turnover		 209.23 237.21 232.11 285.80 336.94 390.01 317.28 357.59 358.91 385.83
Accounts Payable Turnover		 11.57 10.20 9.02 12.72 13.29 5.54 7.99 10.04 7.80 4.39
Days Sales Outstanding (DSO)		 15.19 14.53 31.28 31.56 30.06 29.31 41.66 41.99 42.14 44.16
Days Inventory Outstanding (DIO)		 84.13 77.87 86.17 79.22 62.31 78.84 101.32 90.67 84.14 93.27
Days Payable Outstanding (DPO)		 31.55 35.78 40.49 28.69 27.47 65.92 45.68 36.36 46.81 83.21
Cash Conversion Cycle (CCC)		 67.77 56.62 76.96 82.09 64.90 42.23 97.30 96.29 79.47 54.23
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 14 2.03 185 197 215 234 236 220 204 189
Invested Capital Turnover		 10.13 24.35 2.47 2.79 3.05 3.38 1.95 2.09 2.20 2.33
Increase / (Decrease) in Invested Capital		 -9.89 -14 163 176 201 232 50 23 -11 -45
Enterprise Value (EV)		 1,063 1,637 1,604 1,247 1,112 1,638 1,374 1,441 1,902 1,950
Market Capitalization		 1,319 1,936 1,752 1,426 1,246 1,792 1,699 1,830 2,360 2,489
Book Value per Share		 $2.63 $2.89 $3.16 $3.54 $3.27 $3.64 $4.81 $5.15 $5.57 $6.10
Tangible Book Value per Share		 $2.30 $2.57 $1.42 $1.88 $1.70 $1.82 $3.23 $3.67 $4.17 $4.79
Total Capital		 270 300 334 375 349 388 561 609 661 728
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -256 -298 -148 -179 -134 -154 -326 -389 -457 -539
Capital Expenditures (CapEx)		 0.00 0.00 0.07 0.00 0.06 0.09 0.20 0.01 0.26 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -24 -35 -6.05 9.68 13 5.63 15 6.42 -8.73 -15
Debt-free Net Working Capital (DFNWC)		 232 263 142 188 134 143 325 382 434 503
Net Working Capital (NWC)		 232 263 142 188 134 143 325 382 434 503
Net Nonoperating Expense (NNE)		 -0.79 -1.70 -1.35 -1.41 4.73 -3.74 -1.57 -1.13 -4.83 -8.55
Net Nonoperating Obligations (NNO)		 -256 -298 -148 -179 -134 -154 -326 -389 -457 -539
Total Depreciation and Amortization (D&A)		 0.55 0.62 6.60 8.57 8.57 9.14 9.43 9.44 9.45 9.46
Debt-free, Cash-free Net Working Capital to Revenue		 -12.74% -16.42% -2.36% 3.19% 3.80% 1.41% 3.56% 1.48% -1.90% -2.97%
Debt-free Net Working Capital to Revenue		 120.79% 122.88% 55.44% 62.21% 38.52% 35.98% 79.02% 87.95% 94.16% 102.28%
Net Working Capital to Revenue		 120.79% 122.88% 55.44% 62.21% 38.52% 35.98% 79.02% 87.95% 94.16% 102.28%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.22 $0.24 $0.28 $0.36 ($0.29) $0.32 $0.20 $0.35 $0.37 $0.46
Adjusted Weighted Average Basic Shares Outstanding		 103.32M 103.37M 105.56M 106.26M 106.57M 106.28M 116.81M 118.18M 118.93M 118.46M
Adjusted Diluted Earnings per Share		 $0.20 $0.23 $0.26 $0.33 ($0.29) $0.33 $0.19 $0.33 $0.35 $0.44
Adjusted Weighted Average Diluted Shares Outstanding		 111.99M 111.38M 113.99M 113.67M 106.57M 113.75M 123.40M 124.66M 125.41M 124.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 104.07M 105.65M 106.08M 106.58M 106.61M 117.86M 118.12M 118.69M 119.27M 121.45M
Normalized Net Operating Profit after Tax (NOPAT)		 22 24 28 36 -26 31 22 40 39 47
Normalized NOPAT Margin		 38.36% 39.12% 33.06% 36.50% -25.35% 28.13% 22.03% 32.33% 30.35% 33.41%
Pre Tax Income Margin		 45.43% 54.33% 43.71% 48.72% -37.03% 42.24% 29.53% 45.46% 44.45% 52.31%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 14.92% 8.31% 4.38% 0.00% 0.00% 0.00% 0.45% 0.43% 0.21% 0.18%

Frequently Asked Questions About Catalyst Pharmaceuticals' Financials

When does Catalyst Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Catalyst Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Catalyst Pharmaceuticals' net income changed over the last 9 years?

Catalyst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $163.89 million in 2024, falling from -$20.23 million in 2015. The previous period was $71.41 million in 2023. View Catalyst Pharmaceuticals' forecast to see where analysts expect Catalyst Pharmaceuticals to go next.

What is Catalyst Pharmaceuticals's operating income?
Catalyst Pharmaceuticals's total operating income in 2024 was $195.12 million, based on the following breakdown:
  • Total Gross Profit: $422.89 million
  • Total Operating Expenses: $227.77 million
How has Catalyst Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Catalyst Pharmaceuticals' total revenue changed from $0.00 in 2015 to $491.73 million in 2024, a change of 49,173,400,000.0%.

How much debt does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals' total liabilities were at $123.78 million at the end of 2024, a 50.5% increase from 2023, and a 2,576.2% increase since 2015.

How much cash does Catalyst Pharmaceuticals have?

In the past 9 years, Catalyst Pharmaceuticals' cash and equivalents has ranged from $13.89 million in 2016 to $517.55 million in 2024, and is currently $517.55 million as of their latest financial filing in 2024.

How has Catalyst Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Catalyst Pharmaceuticals' book value per share changed from 0.67 in 2015 to 6.10 in 2024, a change of 810.8%.


Related Companies

This page (NASDAQ:CPRX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...
Stansberry Research | Sponsored
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored
Trump announcement boosts “next Bitcoin”
President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...
Weiss Ratings | Sponsored